PTP.XETRA PENTIXAPHARM HOLDING N AG
- Market cap
- EUR 72.0M
- P/E
- -
- P/B
- 2.19x
- ROE
- -48.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PTP.XETRA undervalued?
Graham numberThe Graham number of PENTIXAPHARM HOLDING N AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PENTIXAPHARM HOLDING N AG fundamental analysis
No fundamental analysis for PENTIXAPHARM HOLDING N AG yet.
PENTIXAPHARM HOLDING N AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based …
Full company profilePENTIXAPHARM HOLDING N AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PENTIXAPHARM HOLDING N AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 59.0K | 31.0K | 24.0K | 118K | 93.0K | 0.00 |
| Gross Profit | 2.60M | 3.97M | 4.72M | -3.60M | -6.70M | -2.56M |
| Operating Income | -1.64M | -2.18M | -6.16M | -17.6M | -19.6M | -13.2M |
| EBITDA | - | -665K | -5.88M | 2.55M | -15.8M | -9.80M |
| Net Income | -2.49M | -1.96M | -7.64M | -12.8M | -16.5M | -13.8M |
| EPS | -0.10 | -0.08 | -0.30 | -0.52 | -0.67 | -0.54 |
| Balance Sheet | ||||||
| Total Assets | 29.1M | 53.9M | 73.4M | 67.4M | 41.9M | 38.5M |
| Total Liabilities | 1.26M | 15.4M | 24.9M | 18.0M | 6.79M | 10.0M |
| Shareholders' Equity | 27.9M | 38.5M | 48.5M | 49.4M | 35.1M | 28.5M |
| Cash & Short-term Investments | 2.39M | 1.09M | 9.70M | 23.2M | 4.62M | 3.59M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.37M | -2.20M | 2.13M | -4.33M | -18.0M | -10.1M |
| Capital Expenditure | 2.73M | 4.05M | 4.94M | 1.00K | 625K | 0.00 |
| Free Cash Flow | -4.10M | -6.24M | -2.81M | -4.33M | -18.6M | -10.1M |
| Ratios | ||||||
| ROE | -8.9% | -5.1% | -15.8% | -26.0% | -47.1% | -48.6% |
| ROA | -8.6% | -3.6% | -10.4% | -19.1% | -39.4% | -36.0% |
| Net Profit Margin | -4,223.7% | -6,325.8% | -31,829.2% | -10,883.9% | -17,753.8% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PENTIXAPHARM HOLDING N AG dividends
PENTIXAPHARM HOLDING N AG has not paid dividends in the last 5 fiscal years.
Who owns PENTIXAPHARM HOLDING N AG
- Insiders 30.99%
- Institutions 6.16%
- Public & others 62.86%
- Shares outstanding 35.8M
- Free float 18.1M
PENTIXAPHARM HOLDING N AG company profile
- Company name
- PENTIXAPHARM HOLDING N AG
- Ticker
- PTP.XETRA
- ISIN
- DE000A40AEG0
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Fiscal year end
- December
- Address
- Robert-Rössle-Straße 10, Berlin, Germany, 13125
- Phone
- 49 30 9489 2600
- Website
- pentixapharm.com
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
PENTIXAPHARM HOLDING N AG management
7- Dr. Dirk Pleimes M.D.Group CEO, Chief Medical Officer & Member of Management Board · born 1975
- Ms. Jenny ScheweHead of Finance & Controlling
- Mr. Erik MertenChief Technology Officer, Acting COO & Member of Executive Board
- Dr. Patrik KehlerChief Scientific Officer · born 1986
- Dr. Simone PickelHead of Clinical Therapy
- Dr. Antje DanielczykHead of R&D Operations
- Dr. Alessandra BierwagenHead of Regulatory